Michael Goettler
Net Worth

Last updated:

What is Michael Goettler net worth?

The estimated net worth of Mr. Michael Goettler is at least $13,745,085 as of 27 Feb 2023. He owns shares worth $1,465,085 as insider and has received compensation worth at least $12,280,000 in Viatris Inc..

What is the salary of Michael Goettler?

Mr. Michael Goettler salary is $3,070,000 per year as Chief Executive Officer & Executive Director in Viatris Inc..

How old is Michael Goettler?

Mr. Michael Goettler is 58 years old, born in 1967.

What stocks does Michael Goettler currently own?

As insider, Mr. Michael Goettler owns shares in one company:

Company Title Shares Price per share Total value
Viatris Inc. (VTRS) Chief Executive Officer & Executive Director 136,796 $10.71 $1,465,085

What does Viatris Inc. do?

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

VTRS logo
VTRS
Viatris Inc.
$10.71

Michael Goettler insider trading

Viatris Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Dividend Equivalent Units 17,504 N/A N/A
Option
Common Stock 119,975 N/A N/A
Option
Common Stock 8,753 N/A N/A
Option
Common Stock 639 N/A N/A
Option
Dividend Equivalent Units 638 N/A N/A
Purchase
Common Stock 50,352 $9.87 $496,773
Option
Dividend Equivalent Units 2,029 N/A N/A
Option
Restricted Stock Units 84,908 N/A N/A
Option
Common Stock 2,030 N/A N/A
Option
Common Stock 84,908 N/A N/A
Option
Common Stock 1,290 N/A N/A
Option
Common Stock 53,958 N/A N/A
Option
Dividend Equivalent Units 2,578 N/A N/A
Option
Restricted Stock Units 3,499 N/A N/A
Option
Common Stock 3,499 N/A N/A

Viatris key executives

Viatris Inc. executives and other stock owners filed with the SEC: